In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Arcus Biosciences Inc (NYSE: RCUS) closed at $25.14 in the last session, down -1.02% from day before closing price of $25.4. In other words, the price has decreased by -$1.02 from its previous closing price. On the day, 0.94 million shares were traded. RCUS stock price reached its highest trading level at $26.1 during the session, while it also had its lowest trading level at $25.1.
Ratios:
We take a closer look at RCUS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously. On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20. On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Jaen Juan C. sold 82,997 shares for $24.71 per share. The transaction valued at 2,050,599 led to the insider holds 954,063 shares of the business.
Juan Jaen bought 82,997 shares of RCUS for $2,096,504 on Dec 04 ’25. On Nov 26 ’25, another insider, Azoy Alexander, who serves as the Chief Accounting Officer of the company, sold 1,900 shares for $26.00 each. As a result, the insider received 49,400 and left with 27,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 3110535424 and an Enterprise Value of 2015454720. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.96 while its Price-to-Book (P/B) ratio in mrq is 6.18. Its current Enterprise Value per Revenue stands at 8.398 whereas that against EBITDA is -5.522.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.77, which has changed by 0.5634328 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $26.40, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 25.97%, while the 200-Day Moving Average is calculated to be 107.75%.
Shares Statistics:
According to the various share statistics, RCUS traded on average about 1.55M shares per day over the past 3-months and 1750130 shares per day over the past 10 days. A total of 107.10M shares are outstanding, with a floating share count of 74.91M. Insiders hold about 39.46% of the company’s shares, while institutions hold 53.16% stake in the company. Shares short for RCUS as of 1764288000 were 9085675 with a Short Ratio of 5.88, compared to 1761868800 on 8344964. Therefore, it implies a Short% of Shares Outstanding of 9085675 and a Short% of Float of 10.459999999999999.
Earnings Estimates
The stock of Arcus Biosciences Inc (RCUS) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$1.05, with high estimates of -$1.05 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$3.48 and -$3.77 for the fiscal current year, implying an average EPS of -$3.62. EPS for the following year is -$3.99, with 3.0 analysts recommending between -$3.54 and -$4.29.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $25.79M. It ranges from a high estimate of $40M to a low estimate of $16M. As of. The current estimate, Arcus Biosciences Inc’s year-ago sales were $36MFor the next quarter, 7 analysts are estimating revenue of $31.4M. There is a high estimate of $45M for the next quarter, whereas the lowest estimate is $17.8M.
A total of 9 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $254M, while the lowest revenue estimate was $229M, resulting in an average revenue estimate of $238.11M. In the same quarter a year ago, actual revenue was $258MBased on 9 analysts’ estimates, the company’s revenue will be $128.78M in the next fiscal year. The high estimate is $225M and the low estimate is $37M.
